V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Exact Sciences Executive Compensation (FY24)

EXAS · Executive and director compensation, fiscal 2022 to 2024

The paid brief on Exact Sciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 9, 2026Latest filing (8-K): June 16, 2025
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Exact Sciences brief$1,500Get the executive brief
304 figures on this page: 295 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
Chief executive, fiscal 2024
◇
Kevin Conroy
Median of the other named officers
$4,270,661
6 officers, excluding the chief executive
Latest say-on-pay support
=
June 12, 2025
Chief executive pay ratio
◇
To the median employee

More on Exact Sciences

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kevin Conroy: $16,119,899 → $15,539,378 (3.6% lower)
Say-on-pay support: 91.5% → 93.6% (2.1 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Exact Sciences' chief executive and what were they paid?
Kevin Conroy was paid $15,539,378 in total compensation as Chairman, President and Chief Executive Officer for fiscal 2024. Conroy's total moved 3.6% lower from the $16,119,899 reported for fiscal 2023.
What was Exact Sciences' say-on-pay result?
Shareholders supported the say-on-pay proposal with 93.6% of votes cast for or against in favor at the meeting held June 12, 2025 for fiscal 2024.
Which companies are in Exact Sciences' peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., Agilent Technologies, Inc., Align Technology, Inc., Alnylam Pharmaceuticals, Inc. and Bio-Rad Laboratories, Inc., among others.
What is Exact Sciences' chief executive pay ratio?
The company reported a chief executive pay ratio of 109:1 for fiscal 2024, against median employee compensation of $142,608.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Conroy
Chairman, President and Chief Executive Officer
◇—◇—◇—◇◇
Everett Cunningham
Former Executive Vice President and Former Chief Commercial Officer
◇◇◇—◇—◇◇
Jeffrey Elliott
Former Executive Vice President and Former Chief Financial Officer
◇—◇—◇—◇◇
Jacob Orville
Executive Vice President and General Manager, Screening
◇—◇—◇—◇◇
Sarah Condella
Executive Vice President, Human Resources
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Conroy
Chairman, President and Chief Executive Officer
◇—◇—◇—◇◇
Everett Cunningham
Former Executive Vice President and Former Chief Commercial Officer
◇◇◇—◇—◇◇
Jeffrey Elliott
Former Executive Vice President and Former Chief Financial Officer
◇—◇—◇—◇◇
Jacob Orville
Executive Vice President and General Manager, Screening
◇—◇—◇—◇◇
Brian Baranick
Executive Vice President and General Manager, Precision Oncology
◇—◇—◇—◇◇
Sarah Condella
Executive Vice President, Human Resources
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin Conroy
Chairman, President and Chief Executive Officer
◇—◇—◇—◇◇
Aaron Bloomer
Executive Vice President and Chief Financial Officer
◇◇◇—◇—◇◇
Jacob Orville
Executive Vice President and General Manager, Screening
◇—◇—◇—◇◇
Brian Baranick
Executive Vice President and General Manager, Precision Oncology
◇—◇—◇—◇◇
Everett Cunningham
Former Executive Vice President and Former Chief Commercial Officer
Departed during or after this year
◇—◇———◇◇
Jeffrey Elliott
Former Executive Vice President and Former Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Sarah Condella
Executive Vice President, Human Resources
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Aaron BloomerRSU◇——◇——◇
Aaron BloomerRSU◇——◇——◇
Aaron BloomerPSU◇—◇—◇—◇
Brian BaranickRSU◇——◇——◇
Brian BaranickRSU◇——◇——◇
Brian BaranickPSU◇—◇—◇—◇
Everett CunninghamPSU◇—◇—◇—◇
Everett CunninghamRSU◇——◇——◇
Jacob OrvilleRSU◇——◇——◇
Jacob OrvilleRSU◇——◇——◇
Jacob OrvillePSU◇—◇—◇—◇
Jeffrey ElliottRSU◇——◇——◇
Kevin ConroyPSU◇—◇—◇—◇
Kevin ConroyRSU◇——◇——◇
Sarah CondellaPSU◇—◇—◇—◇
Sarah CondellaRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Kevin ConroyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Aaron BloomerRSU◇◇——
RSU◇◇——
RSU◇◇——
Brian BaranickRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Sarah CondellaRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Jacob OrvilleRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Jeffrey ElliottOption◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Barber
◇◇————◇
James Doyle
Lead independent director
◇◇————◇
Paul Clancy
◇◇————◇
Daniel Levangie
◇◇————◇
Katherine Zanotti
◇◇————◇
Kathleen Sebelius
◇◇————◇
Shacey Petrovic
◇◇————◇
D. Scott Coward
◇◇————◇
Timothy Scannell
—◇————◇
Pierre Jacquet, Kimberly Popovits, Leslie Trigg, Freda Lewis-Hall and Kevin Conroy served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • 10x Genomics, Inc. TXG
  • Agilent Technologies, Inc. A
  • Align Technology, Inc. ALGN
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Bio-Rad Laboratories, Inc. BIO
  • Bio-Techne Corporation TECH
  • BioMarin Pharmaceutical Inc. BMRN
  • DexCom, Inc. DXCM
  • Edwards Lifesciences Corporation EW
  • Guardant Health, Inc. GH
  • Hologic, Inc. HOLX
  • Horizon Therapeutics Public Ltd Co HZNP
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Incyte Corporation INCY
  • Insulet Corporation PODD
  • Masimo Corporation MASI
  • Natera, Inc. NTRA
  • Penumbra, Inc. PEN
  • Quidel Corporation QDEL
  • ResMed Inc. RMD
  • Seagen, Inc. SGEN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020June 30, 2021=◇◇◇
2019July 23, 2020=◇◇◇
2018July 25, 2019=◇◇◇
2017July 26, 2018=◇◇◇
2016July 27, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Exact Sciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Exact Sciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Exact Sciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Exact Sciences' disclosed peer group is defensible, who names Exact Sciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
304 figures on this page: 295 cited to the filing that reported them, 9 calculated from figures it prints.
295 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001124140-25-000046
  2. 0001124140-25-000034
    CEO Pay Ratio · Corporate Governance Principles, Board Matters, and Non-Employee Director Compensation · Grants of Plan-Based Awards in 2024
  3. 0001124140-24-000054
  4. 0001124140-23-000054
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001124140-22-000042
  6. 0001124140-21-000070
  7. 0001124140-20-000044
  8. 0001104659-19-042081
  9. 0001104659-18-047428
  10. 0001104659-17-047517
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Exact Sciences executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/EXAS (accessed 2026).
Short form: data: Velarion

The paid brief for Exact Sciences

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Exact Sciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Exact Sciences discloses

The companies named in EXAS's own disclosed peer group.

10x Genomics, Inc.Agilent Technologies, Inc.Align Technology, Inc.Alnylam Pharmaceuticals, Inc.Bio-Rad Laboratories, Inc.Bio-Techne CorporationBioMarin Pharmaceutical Inc.DexCom, Inc.Edwards Lifesciences CorporationGuardant Health, Inc.Hologic, Inc.Horizon Therapeutics Public Ltd CoIDEXX Laboratories, Inc.Illumina, Inc.Incyte CorporationInsulet CorporationMasimo CorporationNatera, Inc.Penumbra, Inc.Quidel CorporationResMed Inc.Seagen, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy